Brain and Behavior Research Foundation

Advisory Panel Recommends FDA Approval of Esketamine, with New Mechanism to Treat Resistant Depression

Advisory Panel Recommends FDA Approval of Esketamine , with New Mechanism to Treat Resistant Depression & Suicidal Thinking

On February 12th, an FDA advisory panel recommended overwhelmingly that the agency approve a drug called esketamine for the rapid relief of depression in patients who have not been helped by existing therapies.

If the FDA follows the advisory panel’s recommendation in a meeting scheduled for March 4th and gives the go-ahead for marketing of the drug, it will mark a new opportunity for an untold number of patients in great need.